"Humans and other mammals"@en . . . . . . . . . . . . . . . . . . . . . "withdrawn"@en . . "116644-53-2"@en . . . "≥ 99%, primarily to alpha 1-acid glycoprotein."@en . . . "Mibefradil is a tetralol calcium channel blocking agent that inhibits the influx of calcium ions across both the T (low-voltage) and L (high-voltage) calcium channels of cardiac and vascular smooth muscle, with a greater selectivity for T channels. Vasodilation occurs in vascular smooth muscle, causing a decrease in peripheral vascular resistance and a resulting decrease in blood pressure. Mibefradil causes a slight increase in cardiac output during chronic dosing. Mibefradil slows sinus and atrioventricular (AV) node conduction, producing a slight reduction in heart rate and a slight increase in the PR interval. It has also been shown to slightly lengthen the corrected sinus node recovery time and AH interval and to raise the Wenckebach point. The mechanism by which mibefradil reduces angina is not known, but is thought to be attributed to a reduction in heart rate, total peripheral resistance (afterload), and the heart rate–systolic blood pressure product at any given level of exercise. The result of these effects is a decrease in cardiac workload and myocardial oxygen demand."@en . . "Bioavailability after a single dose is 70%. After multiple dosing, the proportion of mibefradil undergoing first-pass metabolism is reduced, resulting in a steady state bioavailability of approximately 90%. Food does not affect the rate or extent of absorption of mibefradil."@en . "17 to 25 hours at steady state."@en . . . "Mibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs."@en . . . . . . "Mibefradil"@en . . . "For the treatment of angina and high blood pressure."@en . . .